Biotech Values

[iwfal]

CLDX -

CLDX will pursue high-expressors of GPNMB in triple-negative breast cancer with OS as the primary endpoint in 3rd or 4th line therapy.

Good on them! One of the concerns I stated 6 months ago was that they would pursue a ph iii consistent with the way they presented data several months ago (they kept talking about the wonderful high expressors data overall - when, in fact, virtually all the benefit was in the group that were both high expressors and TN).